Skip to main content
logo
enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
1.850
-0.070 (-3.65%)
At close: Sep 9, 2026, 4:00 PM EDT
1.850
0.00 (0.00%)
After-hours: Sep 9, 2026, 4:43 PM EDT

enGene Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Nov - Oct.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Market Capitalization
124369451343160-
Market Cap Growth
-53.19%-18.18%31.50%113.74%--
Enterprise Value
-109199218438--
Last Close Price
1.857.218.8521.7010.15-

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
PB Ratio
0.562.201.664.73-13.33-
P/TBV Ratio
0.542.201.664.73--

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Debt / Equity Ratio
0.140.190.090.14-2.350.41
Net Debt / Equity Ratio
-1.01-0.97-0.78-0.99-0.65-0.85
Net Debt / EBITDA Ratio
1.711.323.442.77-0.410.48
Net Debt / FCF Ratio
2.241.614.342.86-0.440.46
Quick Ratio
9.826.1316.3315.954.263.93
Current Ratio
10.216.3016.8716.254.434.20
Return on Equity (ROE)
-60.50%-53.28%-31.96%-330.60%--
Return on Assets (ROA)
-31.99%-28.90%-19.56%-29.38%-62.37%-
Return on Capital Employed (ROCE)
-52.30%-65.00%-21.00%-31.90%-103.30%-134.40%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21
Earnings Yield
-105.19%-31.78%-12.22%-29.13%-15.24%-
FCF Yield
-83.92%-27.29%-10.91%-7.31%-11.06%-
Buyback Yield / Dilution
-30.65%-35.30%-5355.08%-5.72%81.61%-28.93%
SEC Filings: 10-K · 10-Q